Vertaling van "continued low relapse rates after " (Nederlands → Frans) :

FTY720 (fingolimod), a novel oral development therapy for multiple sclerosis, showed continued low relapse rates after four years in patients with relapsing-remitting MS in an open-label Phase II extension study. The data, presented at the American Academy of Neurology (AAN) meeting in April, also showed no significant change in the safety profile from three to four years.
FTY720 (fingolimode), nouveau traitement par voie orale de la sclérose en plaques (SEP), a continué de montrer de faibles taux de rechute après quatre ans de traitement de patients souffrant de la forme cyclique (poussées/rémissions) de la SEP, selon les résultats d’un essai ouvert étendu de phase II. Les résultats présentés au congrès de l’American Academy of Neurology, qui a eu lieu en avril, ont également montré que le profil d’innocuité n’avait pas changé en passant de trois à quatre ans.

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

Overall, systemic use of antibiotics is only of limited value due to the low success rate and rapid emergence of resistance but can be considered in exceptional situations after repeated failure of the standard decontamination procedure.
Un recours global et systémique aux antibiotiques n’a qu’une valeur limitée en raison du faible taux de succès et de l’émergence rapide d’une résistance, mais on peut l’envisager dans des situations exceptionnelles, à la suite d’échecs répétés du procédé standard de décontamination.

Taxes The tax rate for continuing operations (taxes as a percentage of pre-tax income) rose to 14.1% in 2008 from the unusually low level of 12.6% in 2007.
Impôts Le taux d’imposition des activités poursuivies (exprimé en pourcentage du résultat avant impôts) a atteint 14,1% en 2008, contre un niveau exceptionnellement bas de 12,6% en 2007.

A discussion of the results with the ward/unit staff concerned should then identify the possible causes of any increase or stimulate the staff (e.g. incentives) to continue their infection prevention efforts in the case of a stable low rate or a decrease.
Une discussion des résultats avec le personnel concerné de la salle/unité devrait alors identifier les causes possibles de toute augmentation ou stimuler le personnel (par exemple à l’aide d’incitants) à continuer leurs efforts de prévention de l’infection en cas de taux faible stable ou de diminution.